Opko Health, Inc.

your telephone keypad to withdraw yourself from the question queue. Press star, then two. Please also note this event is being recorded. And now I'd like to turn the conference over to Yvonne Briggs. Please go ahead.

Thank you, Operator. Good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss Opco Health financial results for the second quarter of 2022. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking, and as such, will be subject to risks and uncertainties that can materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2021, and its subsequently filed SEC reports. The conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 4th, 2022. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format for today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Dr. Elias Zerhouni, Vice Chairman and President of Opco, will then provide an overview of Opco's pharmaceutical business. Dr. John Cohen will discuss bioreference laboratories, and after that, Adam Vogel, Opco's CFO, will review the company's second quarter financial results, then will open up the call to questions. Now I'd like to turn the call over to Dr. Frost.

Good afternoon, and thank you for joining today's call to discuss our second quarter financial results and business progress. Last quarter, we announced the acquisition of Modex Therapeutics, a biotechnology company focused on developing unique, advanced, multi-specific immunotherapies for cancer and infectious diseases. I'm really pleased to say that the integration of Modex into OpcoHealth is proceeding smoothly. We continue to be very enthusiastic about their transformative platform technology, which we believe has the potential to provide better outcomes for patients. These multi-specific antibody technologies and vaccine programs are differentiated from the competition and have garnered significant interest from potential big pharma partners for various applications. We look forward to keeping you apprised of our progress. As I mentioned on our last call, Dr. Elias Zerhouni, the co-founder and chairman of MODX, was appointed president of OPCO and has joined the company's board of directors as vice chairman. Dr. Zerhouni is a former director of the National Institutes of Health and has significant experience in industry as the head of global research and development for Sanofi for nine years. Along with Elias, the MODX team of outstanding scientists bring significant expertise to advance both MODEX and OPCO proprietary pipelines through the clinic. Elias will provide further details on the pharmaceutical business momentarily. Pfizer, a commercial partner for Anginilic or Simetragan, has launched a weekly injectable growth hormone product in Japan and other countries, including Germany, Canada, and Australia. Pfizer believes clinicians and patients will welcome a once-weekly injection therapy versus daily injections, the standard of care for more than 30 years. In the U.S., we continue to work with Pfizer on resolving the FDA's comments regarding the BLA submission. Pfizer remains fully committed to bringing NGINLA to patients globally as soon as possible. Semaphore Holdings announced the closing of their acquisition of GeneDx for $150 million before adjustments, plus 80 million shares of Semaphore common stock. Subject to revenue milestones, ICO may receive an additional $150 million over the next two years, payable in either cash or stock. We look forward to the progress of the combined company. LeaderMed, our joint venture partner in China, is gearing up to commence a phase three trial of auxinthamonduin for the treatment of obesity and type 2 diabetes, now scheduled to begin in early 2023. Also, LeaderMed is preparing to start a clinical trial of our factor VII CTP, a novel long-acting coagulation factor to treat hemophilia. The data from both trials will be available for UPCO to seek regulatory approval in countries outside of China. With that brief overview, I'd like to turn the call over to Elias, and then John will discuss by references quarterly results and initiatives. Elias?